Trial results

Lifestyle Counseling and Medication for Adolescent Weight Management

NCT04873245 on ClinicalTrials.gov · last registry update 2026-07-02

Finished 29 June 2026, after enrolling 120 people. Primary outcome, as filed: Change in body mass index. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P2

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

University of Minnesota

Sponsor type

Other

Enrollment

120

Started

2022-03-15

Primary completion

2026-06-29 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in body mass index

Conditions studied

Obesity, Childhood

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.